Introduction
Assessing the health-related quality of life (HRQOL) of patients is a critical element of care. For patients with diabetes mellitus (DM), the physical burden, emotional consequences, and daily self-care requirements [1] lead to large and well-documented deficits in HRQOL compared with the general population [2] . Low HRQOL may erode the capacity for self-care of patients with diabetes, increasing their risk of complications and comorbidities [1] .
Both generic and disease-specific questionnaires can be used to measure HRQOL among patients with DM [3, 4] . The ShortForm 36 Health Survey (SF-36) [5] , the most common generic HRQOL measure, has been validated for use in populations with DM [3, 6] and is widely used in DM research. Because HRQOL measures are not usually part of routine clinical assessment, clinicians may lack criteria for interpretation of score levels and score differences.
This article aims to help users of the SF-36 answer the following question: "I have found a score difference of X points. Is this difference trivial, small, or large?" Our approach to that question is to link SF-36 scores to four other outcomes whose clinical significance is intuitively clear: mortality, hospitalization, inability to work, and loss of work. We label these outcomes as benchmarks because they provide a standard by which to evaluate the magnitude of a score difference. Thus, we would consider a score difference to be large if it were associated with a notable increase in, for example, mortality risk.
We associate differences in SF-36 scores with relative risks (RRs) of the four outcomes. Building on prior work [5] , we hypothesize that each SF-36 scale is associated with each outcome. We analyze the SF-36 scales as continuous variables and report RRs for a 1-point score difference to allow easy calculations of RRs for other score differences. We present these benchmarks as points of reference for interpreting what constitutes a large or a small score difference even though the associations are not necessarily causal.
While the present study is motivated by the need for interpretation benchmarks within populations with diabetes, we empirically test whether the interpretation depends on disease or other characteristics. General interpretation guidelines across diseases are standard for most physiological measures and have obvious advantages in terms of building a common perspective across different disease areas. The issue, however, has not been thoroughly tested for HRQOL measures.
Methods

Data Sources
This analysis draws on three data sets ( Table 1 ). The Medical Outcomes Study (MOS) was an observational study of functional status and well-being among 3445 chronically ill adult patients with hypertension, non-insulin-dependent diabetes mellitus, recent acute myocardial infarction, congestive heart failure, or depressive disorder from Massachusetts, Illinois, and California [7] . Patients were administered the paper and pencil version 1 of the SF-36 (SF-36v1) in 1986, followed regularly for 4 years with regards to health and well-being, and checked at 7 years regarding mortality.
The Medicare Health Outcomes Survey (MHOS), which we used for analysis of mortality, is a large, ongoing governmentfunded study assessing the physical and mental health of Medicare beneficiaries enrolled in managed care plans across the United States [8] . Each MHOS cohort is prospectively followed 16  18  29  34  8  12  High school  30  34  38  37  30  37  Some college  27  27  33  30  31  29  College or more  27  21  30  22  Female (%)  62  56  58  53  51  44  Married (%)  59  64  54  54  52  54  SF-36 Ã MOS: 7-y mortality, MHOS: 2-y mortality. † Five comorbidities were measured in all three data sets: angina, chronic heart failure, chronic obstructive pulmonary disease, diabetes, and myocardial infarction. ‡ Total comorbidities were MOS, 9; MHOS, 11; and QM Norms, 21. § SDs of all SF-36 scores vary from 10.0 to 13.6 ║ High scores in the diabetes group relative to total is likely due to the large proportion of patients with clinical depression in the comparison group. V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 9 3 -1 0 0 0 for 2 years; the last cohort to complete the SF-36v1 (by paper and pencil) was cohort 8 (n ¼ 78,183), which was selected in 2005.
The cross-sectional QualityMetric Patient-Reported Outcome Norming Survey (QM Norms), which we used for analysis of ability to work, administered version 2 of the SF-36 (SF-36v2) via Internet to a nationally representative sample of 4040 adults in the United States in 2009 [5] . The major difference between v1 and v2 of the SF-36 is an improvement in the response options for the items concerning role limitations, reducing the ceiling problems of these scales [5] . The QM Norms study also includes selfreported measures of morbidity, employment status, and health resource use.
Variables
The studies recorded age, education, and marital status with various degrees of detail (Table 1) . We collapsed marital status into married/not married to avoid small groups. Respondents in all three studies also completed checklists of their current health conditions: the MOS list included 9 conditions, the MHOS 12, and the QM Norms 21. Included in all three checklists were diabetes, angina, chronic heart failure, chronic obstructive pulmonary disease, and myocardial infarction.
The SF-36 yields scores for eight scales: Physical Functioning (PF), Role Limitations due to Physical Health (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Limitations due to Emotional Health (RE), and Mental Health (MH). These scale scores can be combined to produce two component summary scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). To aid interpretation, norm-based scoring has been introduced for the SF-36 [5] , setting the general population mean to 50 and the SD to 10 for all scales. Scores typically range from 20 to 60, with higher scores indicating better health [5] .
In the MOS, mortality was assessed as date of death with censoring 7 years after baseline, providing 20,400 person-years of follow-up. In the MHOS, death was recorded as a dichotomous variable at 2-year follow-up.
Hospitalization (overnight stay in hospital) was assessed in the MOS through self-report at the 6-month follow-up.
Inability to work due to health was assessed at baseline in the MOS and the QM Norms. MOS respondents who were neither working (full or part time), retired, nor homemakers were asked the question "Does your health keep you from working at a paying job?" The QM Norms study asked all respondents, "Are you now working at a paying job?" and we defined inability to work due to health by the response "No, because of my health."
Lost ability to work 6 months after baseline was defined in the MOS as those who were not constrained from working because of their health at baseline, but were so at the 6-month follow-up.
Statistical Modeling
We performed separate analyses for each combination of the SF-36 scales and the four outcomes. The MOS mortality data were analyzed by using a Cox proportional hazards model. Fit was evaluated through the supremum test of the proportional hazards assumption and through Martingale Residuals [9] .
For the other outcomes (hospitalization, ability to work, and loss of ability to work), we used logistic regression models because they provided better fit than Poisson regression models [10] in terms of the Akaike Information Criterion [11] . We further evaluated fit of the logistic regression model through the Hosmer-Lemeshow statistic [12] .
All analyses included age, sex, education, marital status, and medical conditions. We did not mutually control for other SF-36 scales. Because the same disease process often affects several HRQOL outcomes, including several SF-36 scales would bias the results to underestimate the strength of the association. We evaluated models that used each medical diagnosis as an independent variable, but found that a sum scale counting the number of conditions provided better fit according to the Hosmer-Lemeshow statistic. We tested whether the association between SF-36 scale scores and the outcomes depended on diagnosis. This was done by defining a class variable for type of diagnosis (with "no diagnosis" as comparison category) and testing the interaction between this variable and scale score. To avoid the problem of classifying patients with multiple conditions, these analyses were restricted to subsamples of respondents with one or no diagnosis, termed the single disease subsamples below. In the MHOS study, the variable defined 12 diagnoses. In the MOS and QM Norms studies, we used three categories (diabetes, other disease, and no diagnosis) to avoid small groups.
In each analysis, the SF-36 scale or component summary score was included as a continuous variable. We tested for nonlinear effects by including quadratic and cubic terms in the models. To avoid spurious nonlinear effects, all SF-36 scores were recentered so that 50 were set to 0. We tested whether the association between the SF-36 score and the outcome depended on age, sex, education, marital status, or number of comorbidities by including interaction terms between each background variable and the score. In the MOS and QM Norms data, age was recentered at age 50 years. Only significant nonlinear terms and interaction terms were kept in the final model. Because of multiple tests, we used a Bonferroni corrected alpha level, correcting for the number of independent variables, interactions, and nonlinear terms included in each analysis. The detailed results can be found in Supplemental Materials found at http:// dx.doi.org/10.1016/j.jval.2013.06.022.
The scoring of PCS and MCS involves negative weights for some scales: the PF, RP, and BP scales for the MCS and the RE and MH scales for the PCS [13] . In particular, MCS scores of 58 or more occur together with low PF and RP scores. Because this may cause nonlinear results, we excluded cases with MCS scores of 58 or more in all models that include the MCS as a predictor. This criterion excluded 1% of the full sample and 2% of the diabetic subsample in the MOS, 32% of the full sample and 34% of the diabetic sample in the MHOS, and 23% of the full sample and 26% of the diabetic sample in the QM Norms study.
Interpreting Results
To ease interpretation, parameters from the final models were transformed into RRs for a 1-point score difference-that is, the RR of the outcome in question for a group that had a 1-point lower score than the comparison group. For the proportional hazards model, the log hazard is directly transformed into an RR. In case of interactions or nonlinear effects, we calculated a range of RRs to illustrate potential variability.
For the logistic regression model, we estimated the RR in the following way: 1) we used the logistic regression model parameters to calculate the probability of the outcome for a given combination of values for the SF-36 score and other covariates, and 2) we then repeated the calculation for a score level 1 point lower and calculated the RR as the ratio of the two probabilities. If the outcome is common, the RR may not be constant even if the model includes no interactions or nonlinear effects. Therefore, we present a range of RRs from these analyses.
We calculated average RRs for patients with diabetes by using the model parameters to calculate the linear predictor for each patient with diabetes and taking the average across the diabetes sample. We then repeated the calculation for a hypothetical diabetes sample that had the same distribution of covariates, V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 9 3 -1 0 0 0 but a 1-point lower SF-36 scale score. Finally, we transformed the two linear predictors to calculate the average RRs for the diabetes samples.
Results
Mortality
In the MOS, the fit tests suggested that scores for the PF, GH, VT, and PCS should be modeled as time-dependent effects, assuming one level of association for the first 2 years after baseline and another for years 3 through 7. Significant associations between score and mortality were found for the PF, RP, GH, VT, and SF scales and for the PCS (P o 0.0025 for all tests). In the MHOS, significant associations were found for all scale and component summary scores (P o 0.0001). In both the MOS and the MHOS single disease subsamples, the associations between score and mortality were robust across diseases and no test of interaction between diagnosis and scale score was significant. In the analyses described here, as well as in all subsequent analyses, the final model fit was satisfactory, in that there was no statistically significant misfit. Table 2 presents the estimated RRs of mortality for a 1-point lower SF-36 score. In the MOS, we found interaction effects with age for the PF and GH scales and for the PCS. Associations were much stronger in the younger age groups (RR 1.13-1.14 for persons 40 years old) than in the older age groups (RR 1.01-1.04 for persons 80 years old). In the MHOS study, significant age interactions were found for all scales and for the MCS (P o 0.0001), but not for the PCS. The age interaction effects were less strong than in the MOS, with the largest RRs (up to 1.08) in the 65-to 74-year-old group and smaller RRs in the younger and older age groups. Also, in the MHOS, nonlinear effects of scale score were found for all scales except the MH, implying that association with mortality depended on score level and was strongest for low score levels (RR 1.08-1.13, top row Fig. 1 ). In contrast, the MH scale and both component summary scores show constant associations with mortality across the score range. The second row of Figure 1 illustrates the absolute risk of 2-year mortality for V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 9 3 -1 0 0 0 different score levels (assuming age o 65 years, male, college education, married, one diagnosis). For the GH scale, for example, the risks are 2.4% for a score of 50 and 13.1% for a score of 20.
We also found interaction effects with number of comorbidities for all scales except the RP and for the MCS. The largest RRs were found for persons with few or no diagnoses. Finally, for many scales we found weak interaction effects with education and with marital status. Despite statistical significance, these interactions had only a minor impact on the RRs.
The bottom part of Table 2 depicts the average RRs estimated for the subsamples with diabetes in the MOS and the MHOS.
In the MOS data, a 1-point lower score on the PF, GH, and PCS was associated with an RR of 1.09 for mortality. Associations for the remaining scales were less strong. In the MHOS data, the largest RR estimated for the subsample with diabetes was for the PF, RP, and GH (RR 1.06).
Hospitalization
In the MOS, the PF, RP, BP, GH, VT, and SF scales and the PCS were significantly associated with the risk of hospitalization within 6 months (P o 0.005). We found neither nonlinear effects nor V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 9 3 -1 0 0 0 interaction with any covariates. A 1-point lower score was associated with increased risks of hospitalization ranging from an RR of 1.02 to 1.04 (Table 3 ). In the single disease subsample, the associations were robust across diagnoses.
Work Ability
In both the MOS and QM Norms data, all scales and the two component summaries were significantly associated with current inability to work due to health (P o 0.0001). Quadratic effects were found for the PF and SF scales in the MOS and for the PF scale in the QM Norms study. The QM norms data showed interactions for age (with PF, RP, and PCS), marital status (with PF, RP, GH, VT, and MH), and number of comorbidities (GH and RE). In the single disease subsamples, the associations between score and work ability were robust across diseases. In general, the strongest associations were seen for persons in the high score range, for the young, for persons who were married, and for persons with few or no comorbidities (Table 3) . Thus, for 50-year-olds, comparing PF scores of 49 and 50, the RR for being unable to work due to health was 1.21 in the QM Norms study and 1.15 in the MOS. Comparing PF scores of 19 and 20, the RRs were 1.05 in the QM Norms study and 1.01 in the MOS.
These nonlinear effects are illustrated for the QM Norms study in the third row of Figure 1 , which shows, in particular for the physical scales and for the PCS, a much stronger association with inability to work for average score levels. The last row of Figure 1 shows the absolute risks of being unable to work for different score levels. For the PCS, the risk varies from 0.8% for persons scoring 50 to 38.6% for persons scoring 20.
For some scales, the RRs also varied significantly by marital status. The strongest associations between subscale score and inability to work were found for married respondents ( Table 3) .
The estimated RRs for being unable to work due to health for the subsamples with diabetes were fairly similar in the MOS and (Table 3, bottom) . For example, the estimated RRs for a 1-point PF score difference were 1.12 in the QM Norms sample and 1.11 in the MOS.
Finally, in the subgroup of the MOS that was able to work at baseline, all scales were significantly associated with loss of ability to work at 6-month follow-up (P o 0.005). The associations between score and loss of work ability were robust across diseases, and no test of interaction between diagnosis and scale score was significant. Two scales, the GH and the VT, showed an interaction with age so that the association between score differences and loss of work ability was strongest among the older age groups and very close to an RR of 1 for persons 30 to 40 years old. The estimated RRs for the subpopulations with diabetes ranged from 1.03 to 1.07.
Conclusions
The current analyses aim to provide benchmarks for the interpretation of SF-36 scores and to evaluate whether such benchmarks are robust across disease and population subgroups. We found no significant differences across disease groups, but significant differences in RRs across important background variables, particularly age, and by score level. These results suggest that specific benchmarks for interpretation can be established for a patient group on the basis of typical distribution of baseline score, age, and other characteristics.
Some of our results raise new questions for research. For example, the 1-point relative risk for mortality in the MHOS varies by score level for most of the subscales but is constant for the PCS. A possible reason may be that floor and ceiling effects cause variations in relative risks for the SF-36 subscales. Floor and ceiling effects are seen to a much lesser extent in the PCS.
The RRs presented for a 1-point score difference can be used to calculate benchmarks for other score differences. For example, we estimated that a 1-point lower score on the PF, GH, and PCS implied a 9% increased risk of mortality for patients with DM. For a 3-point score difference, a rough approximation of the increased risk is 3 Â 9 ¼ 27% and a closer approximation is the RR (1.09) to the power of 3 ¼ 1.30.
The absolute magnitudes of the risks are important to bear in mind. For example, in the MHOS study, the absolute risk of mortality varied from 2.8% to 9.0% in the PF score range 50 to 20. For an absolute risk around 9%, an RR of 1.30 implies a risk difference of 2.7%. For an absolute risk around 2.8%, the risk difference for the same RR is 0.8%. For inability to work, the relative risk was lower for low scores levels, where the absolute risk was high. Part of the reason is that a constant odds ratio is equivalent to a lower RR when the outcome is frequent.
HRQOL research on benchmarks for interpretation has often focused on the minimally important difference (MID). MIDs are usually determined through a multifaceted approach including patient ratings of importance of changes, as well as benchmarks such as the ones included in this article. General recommendations for MIDs for the SF-36 range from 2 to 4 points for different scales and score levels [5] . Yet, interpretation remains difficult when an observed difference is statistically significant and smaller than the MID [14] . In standard medical decision making, the potential benefit of a treatment is weighted against the potential costs, such as economic costs, risk of side effects, and so forth, yet the concept of MID disregards the cost part of this equation. Thus, while MIDs are useful as rough guidelines for determining sample size in clinical studies [5, 15] , we hope that the presented benchmarks for interpretation can enable a more nuanced discussion of the interpretation of results.
In DM research, small differences in SF-36 scores are common. Differences in clinical variables [16] or various treatments produce small but statistically significant SF-36 differences, especially for educational/behavioral interventions and some insulin therapies [6] .
The benchmarks discussed in the article should be interpreted on a group level. For an individual, only score changes of 3 to 6 points can be reliably detected [5] . Any mean group change, however, will reflect the balance of a range of individual responses from clinically important deterioration, over stable states, to clinically important improvement. Thus, similar to medical indicators such as blood pressure, group differences that are too small to be measured on an individual level (e.g., a 2 mm Hg difference) may have important public health consequences [17] .
The associations between score differences and work ability were stronger for values of the background variables that are normally associated with better health: younger age, married status, fewer comorbid conditions, and higher SF-36 scores. Thus, benchmarks such as work ability appear to be the most relevant for the large proportion of patients with DM in relatively good health. A possible reason is that people in poor health may have developed coping strategies that allow them to work even in the case of worsening of symptoms and function.
In the MOS mortality analyses, the associations were strongest in the young age groups for the PF and GH scales and the PCS. In the MHOS, the weakest associations were usually seen for participants younger than 65 years. Medicare recipients, however, younger than 65 years constitute a special group with rather severe disabilities that are likely to act as confounders in the analyses. Thus, the MOS results regarding age seem the most trustworthy. Furthermore, although the differences were small, associations in the MHOS were strongest for persons with college education, married status, and few comorbidities. This suggests that, similar to the results for work ability, the association between SF-36 scores and mortality are strongest for patients with DM who are not at high risk according to other risk factors. Contrary to the results for work ability, however, the associations were strongest for persons with low SF-36 scores, suggesting that mortality is most useful as a benchmark for patients with DM having SF-36 scores in the low range.
Our results agree with the results of numerous other studies regarding the association between SF-36 scores and mortality [18] , hospitalization [19] , and work ability [20] . Our observation that the strength of these associations, however, may depend on score level and background factors has so far received little attention [15] .
While we regard our analyses as helpful for interpretation guidelines, their limitations should also be noted. We do not claim that the associations necessarily reflect causal relationships. In most instances, the associations will reflect a causal effect of some disease process on mortality, hospitalization, or work ability, but because the SF-36 scales do not measure specific disease processes, a beneficial effect of a treatment on SF-36 scores may reflect other disease processes than the ones responsible for the associations examined in this article. Also, our analyses have been limited by the available data, which focus mainly on physical health rather than mental health. Studies on additional relevant outcomes, such as overall medical expenditure, sick days, and objective assessment of work productivity, could offer additional important benchmarks for interpretation. The three studies discussed in this article reflect different samples that are not comparable; however, we regard this as a strength of our study because it has allowed us to evaluate robustness of results across samples. Finally, the presented RRs do not take the statistical uncertainty into account. Thus, 10 of the 457 RR estimates presented here were slightly less than 1 (varying from 0.979 to 0.996). We take these estimates as artifacts V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 9 3 -1 0 0 0 of the overall modeling equations rather than evidence of truly reduced risk of outcomes with lower SF-36 scores. While sample sizes were generally large, some uncertainties were seen, in particular in the parameter estimates from the MOS and QM Norms studies. The satisfactory agreement between the two studies regarding the results on work ability, however, provides some support that the results are robust.
In conclusion, we estimate that for patients with diabetes, a 1-point lower score on the PF and GH scales and the PCS was associated with a 5% to 9% increased mortality risk. A 1-point lower score on the PF, RP, BP, GH, VT, and SF scales and the PCS implied a 2% to 4% increased risk of hospitalization in the next 6 months, a 7% to 12% increased risk of being unable to work, and a 4% to 7% increased risk of losing the ability to work over the next 6 months. We propose to use these results as benchmarks for the interpretation of SF-36 results in studies of diabetes [16] .
